Stratrix
Company data sheet · Endo International

Endo International: from profit to seven straight losses.

Industry
Pharmaceutical Preparations Manufacturing
Headquarters
Ireland
Sources
SEC filings (2013–2025), Stratrix's verified Decision Cases, market data and official economic statistics for Ireland
Data as of
November 2, 2026
  1. From profit to seven straight losses. Endo International lost money every year from 2013 to 2019: $9.7 billion in all. 2020 was its first profit in eight years: $0.2 billion.
  2. Left behind by its peers. From 2016 to 2023, its revenue shrank 50% in US dollars; the median among 636 large manufacturers grew 47%. It outgrew only 2% of them.
  3. Still smaller than it was. Revenue reached $2 billion in 2023, 50% below its 2016 peak of $4 billion.
  4. Leaders came and went. Endo International filed 29 leadership changes since 2016, more than 75% of large manufacturers (the median is 20).

Financial results

Fiscal yearRevenueNet income
2016$4 billion−$3.3 billion
2017$3.5 billion−$2 billion
2018$2.9 billion−$1 billion
2019$2.9 billion−$0.4 billion
2020$2.9 billion$0.2 billion
2021$3 billion−$0.6 billion
2022$2.3 billion−$2.9 billion
2023$2 billion−$2.4 billion

As reported in its annual filings. Losses in red.

Has Endo International had layoffs?

Headcount, as reported

Annual reportEmployeesAs of
10-K for 20213,103February 21, 2022
10-K for 20222,861February 27, 2023
10-K for 20232,931February 28, 2024

Job cuts, severance and restructuring

  1. The company announced in November 2020 a set of strategic actions called the 2020 Restructuring Initiative to further optimize operations and increase efficiency, which it reports it has been progressing. In November 2020

    “In November 2020, we announced the initiation of several strategic actions, collectively referred to as the 2020 Restructuring Initiative, to further optimize operations and increase overall efficiency.” 10-K for 2021
  2. The filing reports that 2021 amounts include a net pre-tax reversal of expense, mainly for severance costs that were avoided for employees who moved to buyers in certain site sales. 2021 · Cost: A net pre-tax reversal of expense

    “Discontinued Operations and Note 4. Restructuring in the Consolidated Financial Statements included in Part IV, Item 15 of this report, amounts in 2021 include a net pre-tax reversal of expense, primarily related to avoided severance costs for employees that transitioned to the purchasers in connection with certain site sales.” 10-K for 2021
  3. The filing describes a 2020 restructuring initiative that included a workforce reduction, with employee separation costs recorded under it; the text supplied does not give the number of positions cut.

    “endp:RestructuringInitiative2020Member 2020-11-01 2020-11-30 endp:position” 10-K for 2022
  4. The company announced further actions to stop producing and selling QWO, which it calls the 2022 Restructuring Initiative, aimed at generating cost savings. In December 2022

    “In December 2022, we announced we would be taking certain additional actions to cease the production and sale of QWO ® in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloration.” 10-K for 2023
Reported in the company's financial data (XBRL), each linked to its filing
Fiscal year endedSeverance costs
2016-12-31$60.2 million
2017-12-31$53 million
2018-12-31$31.7 million

Endo International filed 6 restructuring notices (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.

What has Endo International acquired?

Deals its annual reports describe

BusinessDealWhenValue
BioSpecifics Technologies Corp.
“As further described in Note 5. Acquisitions and Note 12. License and Collaboration Agreements in the Consolidated Financial Statements included in Part IV, Item 15 of this report, we completed our acquisition of BioSpecifics Technologies Corp., a Delaware corporation and a commercial-stage biopharmaceutical company (BioSpecifics) in December 2020.” 10-K for 2021
acquisitionDecember 2020—
retail generics business assets
“For example, as further discussed in Note 3. Discontinued Operations in the Consolidated Financial Statements included in Part IV, Item 15 of this report, in 2021, we divested of certain assets related to our retail generics business, as well as certain associated liabilities.” 10-K for 2021
divestiturein 2021—
Litha Healthcare Group Limited, certain assets acquired from Aspen Holdings, and Grupo Farmacéutico Somar, S.A.P.I. de C.V.
“In 2017, we divested of both Litha Healthcare Group Limited and certain assets acquired from Aspen Holdings in October 2015 and Grupo Farmacéutico Somar, S.A.P.I. de C.V.” 10-K for 2021
divestiture2017—
Auxilium Pharmaceuticals
“Prior to Aralez, Dr. Tursi was Chief Medical Officer and Vice President of Clinical R&D at Auxilium Pharmaceuticals until its acquisition by Endo in 2015.” 10-K for 2021
acquisition2015—
Nevakar Injectables, Inc., a subsidiary of Nevakar, Inc.
“In May 2022, we announced that our EVL subsidiary had entered into an agreement to acquire six development-stage RTU injectable product candidates from Nevakar Injectables, Inc., a subsidiary of Nevakar, Inc., for an upfront cash payment of $35.0 million, which was recorded as an Acquired in-process research and development charge in the Consolidated Statements of Operations in the second quarter of 2022.” 10-K for 2022
agreed acquisitionIn May 2022$35.0 million
six development-stage RTU injectable product candidates from Nevakar Injectables, Inc.
“• In May 2022, we announced that we had entered into an agreement to acquire six development-stage RTU injectable product candidates from Nevakar Injectables, Inc., a subsidiary of Nevakar, Inc., for an upfront cash payment of $35.0 million, which was recorded as an Acquired in-process research and development charge in the Consolidated Statements of Operations in the second quarter of 2022.” 10-K for 2023
acquisitionMay 2022$35.0 million
Reported in the company's financial data (XBRL), each linked to its filing
Fiscal year endedCash paid for acquisitions (net of cash acquired)Cash received from selling businessesGoodwill from acquisitions
2016-12-31$30.4 million$10.9 million$93.6 million
2017-12-31$0$223.2 million—
2018-12-31$0$70.4 million—
2019-12-31—$6.6 million—
2020-12-31—$6.7 million—
2021-12-31—$30.3 million—
2022-12-31—$41.4 million—
2023-12-31—$5.1 million—

Deal filings since 2016

Who are Endo International's competitors?

Who Endo International names

CompanyNamed in
Amgen, Inc.2023
Amneal2023
Aurobindo Pharma Limited2023
Jazz Pharmaceuticals plc2023
Sandoz2023
Takeda Pharmaceutical Company Limited2023
Teva Pharmaceutical Industries Limited2023
Viatris Inc.2023

In its own words

  1. Amgen, Inc., Jazz Pharmaceuticals plc, Takeda Pharmaceutical Company Limited, Viatris Inc.

    “This segment’s major competitors, including Viatris Inc. (Viatris), Jazz Pharmaceuticals plc (Jazz), Takeda Pharmaceutical Company Limited and Amgen, Inc., among others, vary depending on therapeutic and product category, dosage strength and drug-delivery systems, among other factors.” 10-K for 2023
  2. Amneal, Aurobindo Pharma Limited, Sandoz, Teva Pharmaceutical Industries Limited

    “Our major competitors, including Teva Pharmaceutical Industries Limited, Viatris, Sandoz, Aurobindo Pharma Limited and Amneal, among others, vary by product.” 10-K for 2023

What are Endo International's subsidiaries?

Subsidiaries it lists

SubsidiaryJurisdiction
70 Maple Avenue, LLCDelaware
Actient Pharmaceuticals LLCDelaware
Actient Therapeutics, LLCDelaware
Anchen IncorporatedNew York
Anchen Pharmaceuticals, Inc.Delaware
Astora Women's Health Bermuda ULCBermuda
Astora Women's Health Ireland LimitedIreland
Astora Women's Health Technologies Ireland—
Astora Women's Health, LLCDelaware
Auxilium International Holdings, LLCDelaware
Auxilium Pharmaceuticals, LLCDelaware
Auxilium US Holdings, LLCDelaware
Bermuda Acquisition Management LimitedBermuda
BioSpecifics Technologies LLCDelaware
Branded Operations Holdings, Inc.Delaware
CPEC LLCDelaware
DAVA International, LLCDelaware
DAVA Pharmaceuticals, LLCDelaware
Endo Aesthetics LLCDelaware
Endo Bermuda Finance LimitedBermuda
Endo Designated Activity CompanyIreland
Endo Eurofin Unlimited CompanyIreland
Endo Finance IV Unlimited CompanyIreland
Endo Finance LLCDelaware
Endo Finance Operations LLCDelaware
Endo Finco Inc.Delaware
Endo Generics Holdings, Inc.Delaware
Endo Global Aesthetics LimitedIreland
Endo Global Biologics Unlimited CompanyIreland
Endo Global Development LimitedIreland
Endo Global Finance LLCDelaware
Endo Global VenturesBermuda
Endo Health Solutions Inc.Delaware
Endo India Holdings, LLCDelaware
Endo Innovation Valera, LLCNew York
Endo Ireland Finance II LimitedIreland
Endo LLCDelaware
Endo Luxembourg Finance Company I S.a r.l.Luxembourg
Endo Luxembourg Holding Company S.a r.l.Luxembourg
Endo Luxembourg International Financing S.a r.l.Luxembourg
Endo Management LimitedIreland
Endo Par Innovation Company, LLCDelaware
Endo Pharmaceuticals Finance LLCDelaware
Endo Pharmaceuticals Inc.Delaware
Endo Pharmaceuticals Solutions Inc.Delaware
Endo Pharmaceuticals Valera Inc.Delaware
Endo Procurement Operations LimitedIreland
Endo TopFin LimitedIreland
Endo U.S. Inc.Delaware
Endo US Holdings Luxembourg I S.a r.l.Luxembourg
Endo Ventures Aesthetics LimitedIreland
Endo Ventures Bermuda LimitedBermuda
Endo Ventures Cyprus LimitedCyprus
Endo Ventures Unlimited CompanyIreland
Generics Bidco I, LLCDelaware
Generics International (US) 2, Inc.Delaware
Generics International (US), Inc.New York
Generics International Ventures Enterprises LLCPennsylvania
Hawk Acquisition Ireland LimitedIreland
Innoteq, Inc.Delaware
JHP Acquisition, LLCDelaware
JHP Group Holdings, LLCDelaware
Kali Laboratories 2, Inc.Delaware
Kali Laboratories, LLCNew Jersey
Luxembourg Endo Specialty Pharmaceuticals Holding I S.a r.l.Luxembourg
Moores Mill Properties L.L.C.Delaware
Operand Pharmaceuticals Holdco I LimitedIreland
Operand Pharmaceuticals Holdco II LimitedIreland
Operand Pharmaceuticals Holdco III LimitedIreland
Operand Pharmaceuticals II LimitedIreland
Operand Pharmaceuticals III LimitedIreland
Paladin Labs Canadian Holding Inc.Canada
Paladin Labs Inc.Canada
Par Active Technologies Private LimitedIndia
Par Biosciences Private LimitedIndia
Par Formulations Private LimitedIndia
Par Laboratories Europe, Ltd.England and Wales
Par Pharmaceutical 2, Inc.Delaware
Par Pharmaceutical Companies, Inc.Delaware
Par Pharmaceutical Holdings, Inc.Delaware
Par Pharmaceutical, Inc.New York
Par Sterile Products, LLCDelaware
Par, LLCDelaware
Quartz Specialty Pharmaceuticals, LLCDelaware
Slate Pharmaceuticals, LLCDelaware
Timm Medical Holdings, LLCDelaware
Vintage Pharmaceuticals, LLCDelaware

From Exhibit 21 of the 10-K for 2023. Companies must list their significant subsidiaries there and may leave out smaller ones, so this is the company’s own list, not every entity it owns.

Layoffs, acquisitions, competitors and subsidiaries are read from Endo International’s annual reports (10-K for 2023, 10-K for 2022, 10-K for 2021), as of 2024-03-06.

The full data sheet · Data Plan

Everything behind these findings, ready for your board deck.

  • Market reaction to disclosed decisions: 64 decision filings since 2016, each linked to the SEC, with the share return against its sector and the US market the next day and the next year (0 with market data).
  • Economic context: 6 measures for Ireland, every year since 2016, from the official sources.
  • Peer comparison: against 953 companies of its size in its sector.
  • Financial results: ten years of revenue, operating and net income, and every annual report, linked.
  • Methods and sources, so each number can be checked and cited.

The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.

More from Stratrix

The Business Model Wizard

Make the seven choices that define your model, test your numbers against real companies, and meet the rival AI would build against you.

Free · about twelve minutesBuild your Model Thesis →

Weekly email

Stratonomics, every Tuesday

One data story every Tuesday: what happened, what it means, and the figures you can quote. Free.

We'll email you a link to confirm. Unsubscribe anytime. Privacy policy.